Evidence map›Paper›PMID 24667260›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2014

[The research of clinical pathological features of ALK positive lung cancer in 525 patients and the discussion of detection methods].

Xiang Zhu, Hongwei Li, Baoshan Cao, Chen Liu, Li Liang, Yuxiang Wang, Jiangfeng You, Fei Gao, Xiaolong Ma, Yan Liu and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Xiang ZhuDepartment of Pathology, Peking University, Health Science Center/Peking University Third Hospital, Beijing 100191, China.
Hongwei LiDepartment of Pathology, Beijing Chui Yang Liu Hospital, Beijing 100022, China.
Baoshan CaoDepartment of Oncology and Radiation Sickness, Cancer Center, Peking University Third Hospital, Beijing 100191, China.
Chen LiuDepartment of Radiology, Peking University Third Hospital, Beijing 100191, China.
Li LiangDepartment of Oncology and Radiation Sickness, Cancer Center, Peking University Third Hospital, Beijing 100191, China.
Yuxiang WangDepartment of Pathology, Peking University, Health Science Center/Peking University Third Hospital, Beijing 100191, China.
Jiangfeng YouDepartment of Pathology, Peking University, Health Science Center/Peking University Third Hospital, Beijing 100191, China.
Fei GaoGene Tech (Shanghai) Company Limited, Beijing 100053, China.
Xiaolong MaDepartment of Pathology, Peking University, Health Science Center/Peking University Third Hospital, Beijing 100191, China.
Yan LiuDepartment of Pathology, Peking University, Health Science Center/Peking University Third Hospital, Beijing 100191, China.
Hua WangDepartment of Pathology, Peking University, Health Science Center/Peking University Third Hospital, Beijing 100191, China.
Yan ZhangDepartment of Pathology, Peking University, Health Science Center/Peking University Third Hospital, Beijing 100191, China.
Jian ChenDepartment of Pathology, Peking University, Health Science Center/Peking University Third Hospital, Beijing 100191, China.
Bo ZhangDepartment of Pathology, Peking University, Health Science Center/Peking University Third Hospital, Beijing 100191, China.
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe fusion (rearrangement) of anaplastic lymphoma kinase (ALK) gene has been identified as an import factor to the tumorigenesis and development of lung cancer. ALK tyrosine kinase inhibitors (ALK-TKIs) have been proved to have good effects to ALK positive lung cancers. The increasement of the relevance ratio of ALK will be very important to patients. The aim of this study is to investigate the clinical pathological features of ALK positive lung cancer, and the roles of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in screening and confirming the ALK positive cases in the testing flow of ALK.

methodsIHC analysis of ALK in tumor specimens was performed on 525 lung cancer patients. 34 cases among them were confirmed by FISH.

resultsThe positive incidence of ALK by IHC was 5.14% (27/525). The ALK positive patients were significantly younger than ALK negative patients (P<0.05), and femal was predominant (P<0.05). The proportion of solid predominant adenocarcinoma was significantly higher in ALK positive patients (P<0.05). While acinar and lepidic predominant adenocarcinoma were significantly lower in ALK positive patients (P<0.05). FISH was applied in 34 cases. The coincidence rate was increased with the increasement of positive intensity of IHC staining. All the IHC positive cases with or without EGFR mutation must be confirmed by FISH.

conclusionsIHC is a reliable detection method to screening the ALK in lung cancer, and then enhance the relevance ration. To make a definite diagnosis of ALK positive lung cancer, FISH is a significant detection method.

Indexed as

AdultAgedAged, 80 and overAnaplastic Lymphoma KinaseErbB ReceptorsFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLung NeoplasmsMaleMiddle AgedReceptor Protein-Tyrosine KinasesALK protein, humanAnaplastic Lymphoma KinaseEGFR protein, humanErbB ReceptorsReceptor Protein-Tyrosine Kinases

Identifiers

PMID24667260
PMCPMC6019375
OpenAlexW1916149392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.